DE602005015256D1 - Hetero-oligomere hiv-hüllproteine - Google Patents

Hetero-oligomere hiv-hüllproteine

Info

Publication number
DE602005015256D1
DE602005015256D1 DE602005015256T DE602005015256T DE602005015256D1 DE 602005015256 D1 DE602005015256 D1 DE 602005015256D1 DE 602005015256 T DE602005015256 T DE 602005015256T DE 602005015256 T DE602005015256 T DE 602005015256T DE 602005015256 D1 DE602005015256 D1 DE 602005015256D1
Authority
DE
Germany
Prior art keywords
hiv
different
heterotrimer
env glycoprotein
isolates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005015256T
Other languages
English (en)
Inventor
Leonidas Stamatatos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Biomedical Research Institute
Original Assignee
Seattle Biomedical Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Biomedical Research Institute filed Critical Seattle Biomedical Research Institute
Publication of DE602005015256D1 publication Critical patent/DE602005015256D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602005015256T 2004-12-29 2005-12-28 Hetero-oligomere hiv-hüllproteine Active DE602005015256D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64032904P 2004-12-29 2004-12-29
PCT/US2005/047244 WO2006071933A2 (en) 2004-12-29 2005-12-28 Hetero-oligomeric hiv envelope proteins

Publications (1)

Publication Number Publication Date
DE602005015256D1 true DE602005015256D1 (de) 2009-08-13

Family

ID=36615506

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005015256T Active DE602005015256D1 (de) 2004-12-29 2005-12-28 Hetero-oligomere hiv-hüllproteine

Country Status (10)

Country Link
US (1) US20080248063A1 (de)
EP (2) EP2088155A1 (de)
CN (1) CN101094862A (de)
AT (1) ATE435234T1 (de)
DE (1) DE602005015256D1 (de)
DK (1) DK1831247T3 (de)
ES (1) ES2328507T3 (de)
HK (1) HK1107998A1 (de)
WO (1) WO2006071933A2 (de)
ZA (1) ZA200706186B (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE416795A (de) 1936-08-07 1936-08-31
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US6716429B1 (en) 1997-10-01 2004-04-06 Dana-Farber Cancer Institute, Inc. Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp 41 glycoprotein ectodomain
FR2781676B1 (fr) * 1998-07-31 2004-04-02 Pasteur Merieux Serums Vacc Trimere du produit d'expression du gene env de hiv
WO2001019958A2 (en) * 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Stabilized soluble glycoprotein trimers
DE60035369T2 (de) 1999-12-30 2008-02-28 Dana-Farber Cancer Institute, Inc., Boston Proteoliposomen, die ein integral membranprotein mit einer oder memhreren transmembrandomänen enthalten
AU2002335709B8 (en) * 2001-09-06 2008-12-18 Cornell Research Foundation, Inc. Human Immunodeficiency Virus Envelope Clycoprotein Mutants and Uses Thereof

Also Published As

Publication number Publication date
EP2088155A1 (de) 2009-08-12
EP1831247A2 (de) 2007-09-12
HK1107998A1 (en) 2008-04-25
ES2328507T3 (es) 2009-11-13
WO2006071933A2 (en) 2006-07-06
DK1831247T3 (da) 2009-10-12
ZA200706186B (en) 2008-06-25
ATE435234T1 (de) 2009-07-15
CN101094862A (zh) 2007-12-26
EP1831247B1 (de) 2009-07-01
WO2006071933A3 (en) 2007-02-15
US20080248063A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
Yang et al. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins
JP2019501882A5 (de)
BR0210598A (pt) Complexo solúvel que compreende uma glicoproteìna retroviral de superfìcie
MY145614A (en) Vaccine
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
ATE308558T1 (de) Hiv-1- und hiv-2-peptide zur hemmung von mit membranfusionen in zusammenhang stehenden phänomenen, einschliesslich der übertragung von hiv
DK1159298T3 (da) HIV-peptider, antigener og vaccinekompositioner
WO2007149491A3 (en) Soluble stabilized trimeric hiv env proteins and uses thereof
JP2017501986A5 (ja) 二重特異性hiv−1中和抗体
NO20025153L (no) Fremgangsmåter og sammensetninger for å påvirke formering av HIV-1, HIV-2 og SIV
ES2673972T3 (es) Formas solubles de la glicoproteína G de los virus hendra y nipah
Pinón et al. An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein
ATE509942T1 (de) Nichtproteolysierbare oligopeptide, die das glycoprotein gp41 von hiv inhibieren
WO2002020555A3 (en) Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components
Monteiro et al. Peptide-based fusion inhibitors for preventing the six-helix bundle formation of class I fusion proteins: HIV and beyond
DE602005015256D1 (de) Hetero-oligomere hiv-hüllproteine
WO2007018550A3 (en) Compositions and methods for the detection of hiv-1/hiv-2 infection
JP2006503849A5 (de)
Setiyaningsih et al. Sequence analysis of mRNA transcripts encoding Jembrana disease virus Tat-1 in vivo
WO2010135663A3 (en) Compositions and methods for the detection of hiv-1/hiv-2 infection
ATE391721T1 (de) Modifizierte hiv-1-peptide und ihre verwendung beim nachweisen von anti-hiv-antikörpern
WO2009038605A3 (en) Flexible, polyvalent antiviral dendridic conjugates for the treatment of hiv/aids and enveloped viral infection
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
Shibo Identification of a Small Molecular Anti-HIV-1 Compound that Interferes with Formation of the Fusion-active gp41 Core
RU2004117904A (ru) Комплексное анти-вич соединение

Legal Events

Date Code Title Description
8364 No opposition during term of opposition